Niraparib companion diagnostic - Natera
Latest Information Update: 28 Sep 2024
At a glance
- Originator Natera
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis) in USA
- 04 Aug 2021 Clinical trials in Breast cancer (Diagnosis) in USA
- 04 Aug 2021 GlaxoSmithKline plans phase III ZEST trial for Breast cancer (Diagnosis, Second-line therapy or greater) in August 2021 (PO) (NCT04915755)